Bio

Dr. Bilenker joined Aisling in 2006 and has served as an Operating Partner of Aisling since 2014. He was a full-time employee of Aisling from 2006 and 2014 and served as a Partner from 2012 to 2014. From 2013 until the acquisition of Loxo Oncology (an Aisling portfolio company) by Eli Lilly, Dr. Bilenker served as Loxo’s President and Chief Executive Officer. Prior to Aisling, Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Dr. Bilenker is currently the Chief Executive Officer and Co-founder of Treeline Biosciences. He serves as a director of Gossamer Bio and Sana Biotechnology. His prior board service includes Aragon Pharmaceuticals (acquired by J&J), LENSAR, Loxo Oncology (acquired by Eli Lilly), Roka Bioscience, T2 Biosystems, ViewRay, NCCN Foundation, and BioEnterprise. Dr. Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.